TP53 and lymphoma: In spite of increased penetrance when mice heterozygous for the Tp53 tumor suppressor are crossed with mice harboring mutant Brca1, these mice develop mammary tumors in over one year, at which time development of lymphomas, which is characteristic of p53-deficient background, also compromises animal survival [20].